Skip to content

Australia logo

Main menu
    • Vision, Mission and Values
    • Reports and Resources
    • Diversity, Equity, Inclusion & Belonging
    • Reconciliation Action Plan
    • Environmental, Social & Governance
    • Global Executive Team
    • ANZ Leadership Team
  • Our Products
  • News
  • Join Our Team
  • Contact Us

Visit Organon's LinkedIn Opens a new window

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon ANZ announces Leadership Transition

Save Print

June 18, 2024 11:41 am EDT

Sydney, NSW – 7 June 2024

Organon ANZ today announced that Managing Director Nirelle Tolstoshev will depart the company on 28 June to take up a new opportunity outside of the organisation. 

Nirelle has led Organon ANZ since inception three years ago, and previous to that, was with MSD for 21 years, starting as a Medical Representative in Adelaide, and progressing her career through Sales, Marketing and Business Unit management roles across a number of portfolios.

“Nirelle is known for her passion, personal ‘People First’ approach in managing an incredibly dynamic team, as well as for her innovative thinking to support our founders and the business to grow, said Andreas Daugaard Jørgensen, Managing Director, Asia Pacific.

“Nirelle has an incredible reputation as an authentic and highly skilled business leader with deep expertise in the healthcare environment.  She is recognised as a champion for women in science. I am proud that Nirelle’s growth and experience at Organon has led to new opportunities for her, while she was building a strong foundation for the continued growth and impact of Organon in Australia and New Zealand, Andreas continued.

Organon will initiate the search for a new lead of the operations in Australia and New Zealand. 

You can access further information about Organon Australia at  https://www.organon.com/australia/ and connect with us on LinkedIn.

About Organon

Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialise their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.

Copyright © (2024) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. First issued June 2024.

What can we help you find?

Search for:

Connect with us on social

Linkedin icon Opens a new window
Australia logo
  • Cookie Policy
  • Forward looking statement
  • Privacy Policy
  • Terms of use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies. The Organon Australia website is intended for an Australian audience only. AU-NON-110274. Date of preparation: April 2025.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept